Review of cannabinoid biology and clinical evidence for MS spasticity treatment
Randomized controlled trials confirmed cannabinoid efficacy for MS spasticity, leading to Sativex approval in multiple countries as an add-on treatment for resistant spasticity.
Quick Facts
What This Study Found
This review covered the biological rationale and clinical evidence for cannabinoids in MS spasticity. Anecdotal evidence of cannabis benefits for spasticity was confirmed by randomized, double-blind, placebo-controlled studies.
Sativex (1:1 THC:CBD oromucosal spray) received approval for MS-related spasticity in various countries based on these trials. The review contextualized this within the broader understanding of cannabinoid biology, including the endocannabinoid system's role in regulating neurotransmission and muscle tone.
The authors positioned Sativex as a valuable addition to the existing spasticity treatment armamentarium, particularly for patients not adequately controlled by conventional medications.
Key Numbers
Sativex approved in multiple countries for MS spasticity. 1:1 THC:CBD ratio. Confirmed by randomized, placebo-controlled trials.
How They Did This
Narrative review of cannabinoid receptor biology, endocannabinoid system physiology, and clinical trial evidence for cannabinoids in MS spasticity.
Why This Research Matters
This review provided the scientific justification for using cannabinoids in MS at a time when approvals were being sought in multiple countries. The combination of biological rationale and clinical evidence strengthened the case.
The Bigger Picture
MS spasticity treatment options were limited, and existing drugs often provided insufficient relief with poor tolerability. Cannabinoids added a new treatment class with a different mechanism of action.
What This Study Doesn't Tell Us
Narrative review without systematic methodology. Focused primarily on Sativex rather than other cannabinoid formulations. Treatment effect sizes were modest on average.
Questions This Raises
- ?Are other cannabinoid formulations equally effective?
- ?Can biomarkers predict which patients will respond?
- ?Would higher doses be more effective, or would side effects limit dosing?
Trust & Context
- Key Stat:
- Sativex approved for MS spasticity in multiple countries
- Evidence Grade:
- Narrative review drawing on randomized controlled trial data. Solid evidence base for the specific indication of MS spasticity.
- Study Age:
- Published in 2012. Sativex is now widely available for MS spasticity in approved countries.
- Original Title:
- Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity.
- Published In:
- Therapeutic advances in neurological disorders, 5(5), 255-66 (2012)
- Authors:
- Leussink, Verena Isabell, Husseini, Leila, Warnke, Clemens, Broussalis, Erasmia, Hartung, Hans-Peter, Kieseier, Bernd C
- Database ID:
- RTHC-00580
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is there good evidence for cannabis treating MS spasticity?
Yes. Randomized controlled trials confirmed that Sativex (a 1:1 THC:CBD spray) reduced spasticity symptoms in MS patients. This evidence was strong enough for regulatory approval in multiple countries.
How does it work biologically?
The endocannabinoid system naturally regulates muscle tone and neurotransmission. MS damages the nerves that control these functions. Cannabinoids work by activating this natural regulatory system to reduce the excessive muscle activity (spasticity) caused by MS.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00580APA
Leussink, Verena Isabell; Husseini, Leila; Warnke, Clemens; Broussalis, Erasmia; Hartung, Hans-Peter; Kieseier, Bernd C. (2012). Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity.. Therapeutic advances in neurological disorders, 5(5), 255-66. https://doi.org/10.1177/1756285612453972
MLA
Leussink, Verena Isabell, et al. "Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity.." Therapeutic advances in neurological disorders, 2012. https://doi.org/10.1177/1756285612453972
RethinkTHC
RethinkTHC Research Database. "Symptomatic therapy in multiple sclerosis: the role of canna..." RTHC-00580. Retrieved from https://rethinkthc.com/research/leussink-2012-symptomatic-therapy-in-multiple
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.